Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Exelixis: A Big Yes from the FDA

December 20, 2017 0

Based on statistically significant results from the randomized phase 2 CABOSUN trial in patients with previously …

Portola: The FDA Approves Bevyxxa

December 19, 2017 0

After years of spending efforts in creating and developing its pipeline products, Portola (PTLA) has just been granted …

Cellectis: Offering Proof of Concept is What Led to the Stock Rally

December 14, 2017 0

UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes …

Juno and Spark: On the Road Towards Ambitious Goals

December 12, 2017 0

Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59th American Society of Hematology (ASH) Annual …

Last Week’s Promising News

December 11, 2017 0

The Week in Review #13 From the Prohost Portfolio - 1. Betting on the technology - …

Gilead’s New Acquisition: An Important Step Forward Toward Building a Superior Cancer Franchise

December 8, 2017 0

Gilead Sciences (GILD) has unsurprisingly agreed to acquire Cell Design Labs in a structured buy out …

Practicing More Personalized Medicine

December 5, 2017 0

All the necessities, including future plans, are being taken care of by institutions, academia and biotech …

Prohost Letter #415

December 3, 2017 0

Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of …

Answering Your Questions

December 1, 2017 0

The Week in Review #12 Answering You - Many questions still need answers in the biotech’s …

In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

November 24, 2017 0

On Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed …

Could DelMar Pharmaceuticals’ Drug VAL-083 ($1 Stock Price) Defeat Glioblastoma Multiforme?

November 22, 2017 0

DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview …

A New Trial Demonstrates Promising Results of CAR T Targeting CD-22 for Leukemia Patients.

November 21, 2017 0

The Treatment is Not A New Way as Being Stated, It is Only the Target, Which …

The Week in Review #11

November 20, 2017 0

The Week in Review #11 A New Era - Faster than the speed of light, the management …

The FDA New Guidelines to Speed the Approval of Gene Therapy. See Also: The Gene Editing Effect

November 17, 2017 0

Important news has come from the FDA, which issued new guidelines to speed the introduction of …

Sangamo: In Vivo Editing of the Gene Behind Hunter Syndrome

November 15, 2017 0

Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time …

Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market

November 10, 2017 0

Halozyme Therapeutics (HALO) announced that it will present nonclinical data at the 32nd Annual Meeting of the Society …

Cellectis Allogeneic “Off-the-Shelf” CAR T Candidate is Back in Clinical Trial

November 9, 2017 0

A couple of days ago, Cellectis (CLLS), which uses its own proprietary gene editing technology known …

Nektar Therapeutics: Speeding Its Flight Towards the Moon

November 8, 2017 0

Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s …

The Week in Review #10

November 6, 2017 0

The Week in Review #10 NO CONSPIRACY THEORIES - But this is what’s happening - In …

Yesterday’s Prohost Stocks’ Performances: NBIX UP $11.85; JUNO UP $11.60 and EXEL UP $1.35

November 3, 2017 0

EXELIXIS For Exelixis’ excellent news, please read our latest article, "Exelixis’ (EXEL) Exceptional Financial Results and …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd